IGL-1 : clinical studies

We know that Clinical Studies are key when it comes to discussing the benefits of our solutions: Access here to some available links to clinical studies including IGL-1, preservation solution.

Most of the articles are available in ENGLISH (original language of the article). Chronological classification.

More information about IGL-1

Compared Efficacy of Preservation Solutions in Liver Transplantation: A Long‐Term Graft Outcome Study From the European Liver Transplant Registry.  Adam, R. et al. 2015 🌐

Use of Georges Lopez Institute Preservation Solution IGL-1 in Pancreas Transplantation: A Series of 47 Cases. Igreja, M. et al. 2018 🌐

Graft Protection Against Cold Ischemia Preservation: An Institute George Lopez 1 (IGL-1) and Histidine-tryptophan-ketoglutarate (HTK) Solution Appraisal. A. Panisello-Rosello, et al. 2018 🌐

First clinical multi-center experience of IGL-1 for intestinal  graft preservation. Canovai, E. et al. 2019  🌐

Effect of preservation solutions for static cold storage on kidney transplantation outcomes: A National Registry Study. Legeai, C. et al. 2020 🌐

A Direct Comparison Between Institut Georges Lopez 1 and Histidine-Tryptophan-Ketoglutarate Preservation Solutions in Liver Transplantation. Kiyoshi Takano de Saidneuy et al., 2020 🌐

The effect of IGL-1 preservation solution on outcome after kidney transplantation A retrospective single center analysis. J DeBeule et al 2020🌐

Lower beta cell yield from donor pancreases after controlled circulatory death prevented by shortening acirculatory warm ischemia time and by using IGL-1 cold preservation solution.De Paep DL et al. 2021.🌐

 
Protocol for Maastricht III Organ Recovery – DGMS–DPGOT – Version n°7 November 2019.Corinne Antoine, Régis Bronchard, Laurent Durin. Agence de Biomedecine🌐

Page en construction